{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:58:50Z","timestamp":1790614730661,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"DOI":"10.1007\/s11882-026-01269-2","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:10:05Z","timestamp":1774858205000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Understanding Biologics in CRSwNP: Related Events and Insights"],"prefix":"10.1007","volume":"26","author":[{"given":"Adriana","family":"Izquierdo-Dom\u00ednguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Al-Salloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Vi\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Mullol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isam","family":"Alobid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"issue":"Suppl S29","key":"1269_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European position paper on rhinosinusitis and nasal polyps\u00a02020. Rhinology. 2020;58(Suppl S29):1\u2013464. https:\/\/doi.org\/10.4193\/Rhin20.600.","journal-title":"Rhinology"},{"issue":"3","key":"1269_CR2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.anai.2023.11.001","volume":"132","author":"P Gevaert","year":"2024","unstructured":"Gevaert P, Mullol J, Saenz R, Ko J, Steinke JW, Millette LA, et al. Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status. Ann Allergy Asthma Immunol. 2024;132(3):355-362.e1. https:\/\/doi.org\/10.1016\/j.anai.2023.11.001.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"1269_CR3","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","volume":"146","author":"P Gevaert","year":"2020","unstructured":"Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595\u2013605. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.032. (Erratum in: J Allergy Clin Immunol. 2021 Jan;147(1):416. doi: 10.1016\/j.jaci.2020.11.003. PMID: 32524991.).","journal-title":"J Allergy Clin Immunol"},{"key":"1269_CR4","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M. Efficacy and Safety of Dupilumab in Patients With Severe Chronic Rhinosinusitis With Nasal Polyps (LIBERTY NP SINUS\u201024 and LIBERTY NP SINUS\u201052): Results From Two Multicentre, Randomised, Double\u2010Blind, Placebo\u2010Controlled, Parallel\u2010Group Phase 3 Trials. Lancet. 2019;394:1638\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(19)31881-1.","journal-title":"Lancet"},{"issue":"10","key":"1269_CR5","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","volume":"9","author":"JK Han","year":"2021","unstructured":"Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, et al. Mepolizumab for chronic rhinosinusitis with nasal polypsc (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141\u201353. https:\/\/doi.org\/10.1016\/S2213-2600(21)00097-7. (SYNAPSE study investigators).","journal-title":"Lancet Respir Med"},{"issue":"5","key":"1269_CR6","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/all.16499","volume":"80","author":"S Cai","year":"2025","unstructured":"Cai S, Xu S, Zhao Y, Zhang L. Efficacy and safety of biologics for chronic rhinosinusitis with nasal polyps: a meta-analysis of real-world evidence. Allergy. 2025;80(5):1256\u201370. https:\/\/doi.org\/10.1111\/all.16499. (PMID: 39985317; PMCID: PMC12105074.).","journal-title":"Allergy"},{"issue":"10482","key":"1269_CR7","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","volume":"405","author":"P Gevaert","year":"2025","unstructured":"Gevaert P, Desrosiers M, Cornet M, Mullol J, De Corso E, Keles Turel N, et al. Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials. Lancet. 2025;405(10482):911\u201326. https:\/\/doi.org\/10.1016\/S0140-6736(25)00197-7. (ANCHOR-1 and ANCHOR-2 trial investigators).","journal-title":"Lancet"},{"issue":"12","key":"1269_CR8","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","volume":"392","author":"BJ Lipworth","year":"2025","unstructured":"Lipworth BJ, Han JK, Desrosiers M, Hopkins C, Lee SE, Mullol J, et al. Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps. N Engl J Med. 2025;392(12):1178\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2414482. (WAYPOINT Study Investigators).","journal-title":"N Engl J Med"},{"key":"1269_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjao.2024.100360","volume":"13","author":"JR Wang","year":"2024","unstructured":"Wang JR, Oh E, Aronow B, Bernstein WK. The unseen animal behind medicine: exploring considerations of animal-derived medications and anaesthetics in today\u2019s landscape. BJA Open. 2024;13:100360. https:\/\/doi.org\/10.1016\/j.bjao.2024.100360.","journal-title":"BJA Open"},{"key":"1269_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1693059","volume":"16","author":"H Lababidi","year":"2025","unstructured":"Lababidi H, Bobier C, Rodger D. Animal-derived ingredients in medicines: a framework for ethical prescribing practices. Front Pharmacol. 2025;16:1693059. https:\/\/doi.org\/10.3389\/fphar.2025.1693059.","journal-title":"Front Pharmacol"},{"key":"1269_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.5414\/ALX02533E","volume":"8","author":"U Jappe","year":"2024","unstructured":"Jappe U, Bergmann KC, Brinkmann F, Faihs V, G\u00fclsen A, Klimek L, et al. Biologics in allergology and clinical immunology: Update on therapies for atopic diseases, urticaria, and angioedema and on safety aspects focusing on hypersensitivity reactions. Allergologie. 2024;8:365\u2013406. https:\/\/doi.org\/10.5414\/ALX02533E.","journal-title":"Allergologie"},{"key":"1269_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2025.108343","volume":"248","author":"P Suter","year":"2025","unstructured":"Suter P, Greig R, Chan R, Lipworth B. Efficacy of dupilumab and mepolizumab in eosinophilic COPD: insights from phase 3 trials. Respir Med. 2025;248:108343. https:\/\/doi.org\/10.1016\/j.rmed.2025.108343.","journal-title":"Respir Med"},{"issue":"11","key":"1269_CR13","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S2468-1253(23)00204-2","volume":"8","author":"ME Rothenberg","year":"2023","unstructured":"Rothenberg ME, Dellon ES, Collins MH, Hirano I, Chehade M, Bredenoord AJ, et al. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8(11):990\u20131004. https:\/\/doi.org\/10.1016\/S2468-1253(23)00204-2.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1269_CR14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jdin.2024.03.025","volume":"16","author":"G Yosipovitch","year":"2024","unstructured":"Yosipovitch G, Kim BS, Kwatra SG, Mollanazar NK, St\u00e4nder S, Satoh T, et al. Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2). JAAD International. 2024;16:163\u201374. https:\/\/doi.org\/10.1016\/j.jdin.2024.03.025.","journal-title":"JAAD International"},{"issue":"10","key":"1269_CR15","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1056\/NEJMoa2312382","volume":"390","author":"RA Wood","year":"2024","unstructured":"Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, et al. Omalizumab for the treatment of multiple food allergies. N Engl J Med. 2024;390(10):889\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2312382.","journal-title":"N Engl J Med"},{"issue":"8","key":"1269_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/pai.70174","volume":"36","author":"S Arasi","year":"2025","unstructured":"Arasi S, Pite H, Beken B, Alvaro-Lozano M, Brough H, Caffarelli C, et al. An overview on current practices regarding the diagnosis and management of chronic urticaria in pediatrics: An EAACI task force report. Pediatr Allergy Immunol. 2025;36(8):e70174. https:\/\/doi.org\/10.1111\/pai.70174.","journal-title":"Pediatr Allergy Immunol"},{"issue":"19","key":"1269_CR17","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","volume":"384","author":"A Menzies-Gow","year":"2021","unstructured":"Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2034975.","journal-title":"N Engl J Med"},{"issue":"24","key":"1269_CR18","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","volume":"391","author":"DJ Jackson","year":"2024","unstructured":"Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, Korn S, Pfeffer PE, et al. Twice-yearly depemokimab in severe asthma with anEosinophilic phenotype. N Engl J Med. 2024;391(24):2337\u201349. https:\/\/doi.org\/10.1056\/NEJMoa2406673. (SWIFT-1 and SWIFT-2 Investigators; SWIFT-1 Investigators; SWIFT-2 Investigators).","journal-title":"N Engl J Med"},{"issue":"3","key":"1269_CR19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/15598276221135538","volume":"18","author":"L Tieu","year":"2022","unstructured":"Tieu L, Uchi J, Patel N, Meghani M, Patel P, Nguyen Y. Embracing medication needs of patients based on ethical, dietary, and religious preferences. Am J Lifestyle Med. 2022;18(3):351\u201363. https:\/\/doi.org\/10.1177\/15598276221135538.","journal-title":"Am J Lifestyle Med"},{"issue":"10","key":"1269_CR20","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1016\/j.jaip.2023.06.031","volume":"11","author":"T Ieven","year":"2023","unstructured":"Ieven T, Coorevits L, Vandebotermet M, Tuyls S, Vanneste H, Santy L, et al. Endotyping of IgE-mediated polyethylene glycol and\/or polysorbate 80 allergy. J Allergy Clin Immunol Pract. 2023;11(10):3146\u201360. https:\/\/doi.org\/10.1016\/j.jaip.2023.06.031. (PMID: 37380070; PMCID: PMC10291891.).","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"1269_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s44446-025-00004-8","volume":"33","author":"R Malkawi","year":"2025","unstructured":"Malkawi R, Altahrawi L. Excipients in pharmaceuticals: mechanisms of hypersensitivity and the role of global pharmacovigilance. Saudi Pharm J. 2025;33(4):18. https:\/\/doi.org\/10.1007\/s44446-025-00004-8.","journal-title":"Saudi Pharm J"},{"issue":"5","key":"1269_CR22","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1111\/all.16353","volume":"80","author":"BC Yang","year":"2025","unstructured":"Yang BC, Castells M. Medical algorithm: diagnosis and treatment of drug hypersensitivity reactions to biologicals, 2024 update. Allergy. 2025;80(5):1534\u20139. https:\/\/doi.org\/10.1111\/all.16353.","journal-title":"Allergy"},{"issue":"1","key":"1269_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/all.14984","volume":"77","author":"S Bavbek","year":"2022","unstructured":"Bavbek S, Pagani M, Alvarez-Cuesta E, Castells M, Dursun AB, Hamadi S, et al. Hypersensitivity reactions to biologicals: an EAACI position paper. Allergy. 2022;77(1):39\u201354. https:\/\/doi.org\/10.1111\/all.14984.","journal-title":"Allergy"},{"issue":"8","key":"1269_CR24","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1111\/all.16607","volume":"80","author":"M Pascal","year":"2025","unstructured":"Pascal M, Chauhan J, Knol E, Bianchini R, Castells M, De Las Vecillas L, et al. Basophil activation test: bridging allergy and oncology for diagnostic, therapeutic and prognostic applications in AllergoOncology: an EAACI position paper. Allergy. 2025;80(8):2097\u2013112. https:\/\/doi.org\/10.1111\/all.16607.","journal-title":"Allergy"},{"issue":"4","key":"1269_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s44446-025-00031-5","volume":"33","author":"M Al Gassim","year":"2025","unstructured":"Al Gassim M, Alawami F, Bakhsh GH, Al-Shouli S, Alhumaid NK, Alshehri AA, et al. Towards standardized skin testing for drug-induced allergic reactions. Saudi Pharm J. 2025;33(4):26. https:\/\/doi.org\/10.1007\/s44446-025-00031-5.","journal-title":"Saudi Pharm J"},{"issue":"9S","key":"1269_CR26","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.jaip.2020.08.006","volume":"8","author":"AD Broyles","year":"2020","unstructured":"Broyles AD, Banerji A, Barmettler S, Biggs CM, Blumenthal K, Brennan PJ, et al. Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs. J Allergy Clin Immunol Pract. 2020;8(9S):S16\u2013116. https:\/\/doi.org\/10.1016\/j.jaip.2020.08.006.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"1269_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3238\/arztebl.m2022.0067","volume":"119","author":"I Kremenevski","year":"2022","unstructured":"Kremenevski I, Sander O, Sticherling M, Raithel M, LastName FM. Paradoxical reactions to biologicals in chronic inflammatory systemic diseases. Dtsch Arztebl Int. 2022;119(6):88\u201395. https:\/\/doi.org\/10.3238\/arztebl.m2022.0067.","journal-title":"Dtsch Arztebl Int"},{"issue":"7","key":"1269_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071485","volume":"10","author":"F Miyagawa","year":"2022","unstructured":"Miyagawa F. Pathogenesis of paradoxical reactions associated with targeted biologic agents for inflammatory skin diseases. Biomedicines. 2022;10(7):1485. https:\/\/doi.org\/10.3390\/biomedicines10071485.","journal-title":"Biomedicines"},{"issue":"1","key":"1269_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jamadermatol.2023.4846","volume":"160","author":"A Al-Janabi","year":"2024","unstructured":"Al-Janabi A, Alabas OA, Yiu ZZN, et al. Risk of paradoxical eczema in patients receiving biologics for psoriasis. JAMA Dermatol. 2024;160(1):71\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2023.4846.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"1269_CR30","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1002\/lary.31305","volume":"134","author":"M Dorling","year":"2024","unstructured":"Dorling M, Hernaiz-Leonardo JC, Pascual A, Janjua A, Thamboo A, Javer A. Real-world adverse events after type 2 biologic use in chronic rhinosinusitis with nasal polyps. Laryngoscope. 2024;134(7):3054\u20139. https:\/\/doi.org\/10.1002\/lary.31305.","journal-title":"Laryngoscope"},{"key":"1269_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/lary.32359","author":"AJ Wang","year":"2025","unstructured":"Wang AJ, Jiang R, Runyan T, Abi Hachem R, Goldstein BJ, Jang DW. Adverse effects of dupilumab for chronic rhinosinusitis with nasal polyposis: real-world single institution experience. Laryngoscope. 2025. https:\/\/doi.org\/10.1002\/lary.32359.","journal-title":"Laryngoscope"},{"issue":"10","key":"1269_CR32","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1002\/alr.23453","volume":"14","author":"JB Xiao","year":"2024","unstructured":"Xiao JB, Hsiao H, Khalil C, Lee JM. Rheumatic adverse events associated with biologic therapy for chronic rhinosinusitis: a systematic review and meta- analysis. Int Forum Allergy Rhinol. 2024;14(10):1618\u201333. https:\/\/doi.org\/10.1002\/alr.23453.","journal-title":"Int Forum Allergy Rhinol"},{"issue":"5","key":"1269_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/lio2.70133","volume":"10","author":"R Duggal","year":"2025","unstructured":"Duggal R, Chaaban MR. FDA-Approved biologics for CRSwNP: a five-year analysis of the FDA adverse event reporting system. Laryngoscope Investig Otolaryngol. 2025;10(5):e70133. https:\/\/doi.org\/10.1002\/lio2.70133.","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"3","key":"1269_CR34","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jaip.2024.10.045","volume":"13","author":"H Li","year":"2025","unstructured":"Li H, Wang C, Guo C. A pharmacovigilance analysis of post-marketing safety of tezepelumab. J Allergy Clin Immunol Pract. 2025;13(3):551-558.e6. https:\/\/doi.org\/10.1016\/j.jaip.2024.10.045.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1269_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-025-00777-6","author":"BA Gill","year":"2025","unstructured":"Gill BA, Ijaz A, Fatima N, Ahmed A, Noor A, Sharif S, et al. Efficacy and safety of depemokimab in asthma with eosinophilic phenotype: a systematic review and meta-analysis of randomized controlled trials. BMC Immunol. 2025. https:\/\/doi.org\/10.1186\/s12865-025-00777-6.","journal-title":"BMC Immunol"},{"key":"1269_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/all.70074","author":"A Leonardi","year":"2025","unstructured":"Leonardi A, Bozkurt B, Silva D, Mortz CG, Baudouin C, Atanaskovic-Markovic M, et al. Drug-induced periocular and ocular surface disorders: an\u00a0EAACI position paper. Allergy. 2025. https:\/\/doi.org\/10.1111\/all.70074. (PMID: 41025570.).","journal-title":"Allergy"},{"issue":"4","key":"1269_CR37","doi-asserted-by":"publisher","first-page":"386","DOI":"10.4193\/Rhin24.528","volume":"63","author":"M Lazzeroni","year":"2025","unstructured":"Lazzeroni M, Kemp P, Fokkens WJ, Reitsma S. Eosinophilic complications during dupilumab therapy for type 2 diseases: a systematic review. Rhinology. 2025;63(4):386\u201396. https:\/\/doi.org\/10.4193\/Rhin24.528.","journal-title":"Rhinology"},{"issue":"1","key":"1269_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-44973-z","volume":"13","author":"S Park","year":"2023","unstructured":"Park S, Kim Y, Lee GH, Choi SA. A risk of serious anaphylatic reactions to asthma biologics: a pharmacovigilance study based on a global real-world database. Sci Rep. 2023;13(1):17607. https:\/\/doi.org\/10.1038\/s41598-023-44973-z.","journal-title":"Sci Rep"},{"issue":"5","key":"1269_CR39","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.jaip.2022.12.046","volume":"11","author":"ML Chen","year":"2023","unstructured":"Chen ML, Nopsopon T, Akenroye A. Incidence of anti-drug antibodies to monoclonal antibodies in asthma: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2023;11(5):1475-1484.e20. https:\/\/doi.org\/10.1016\/j.jaip.2022.12.046.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"1269_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105518","volume":"23","author":"YC Tsai","year":"2022","unstructured":"Tsai YC, Tsai TF. Overlapping features of psoriasis and atopic dermatitis: from genetics to immunopathogenesis to phenotypes. Int J Mol Sci. 2022;23(10):5518. https:\/\/doi.org\/10.3390\/ijms23105518.","journal-title":"Int J Mol Sci"},{"key":"1269_CR41","doi-asserted-by":"publisher","unstructured":"Chiei Gallo A, Tavoletti G, Termini D, Avallone G, Barei F, Calzari P, et. al. Phenotypic switch from atopic dermatitis to psoriasis during dupilumab therapy: a real-life experience from a tertiary referral center. Int J Dermatol. 2025. https:\/\/doi.org\/10.1111\/ijd.70105. Epub ahead of print.","DOI":"10.1111\/ijd.70105"},{"issue":"7","key":"1269_CR42","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.88236","volume":"18","author":"ZT O Omar","year":"2025","unstructured":"O Omar ZT, Owodeha-Ashaka M, Okobi OE, Egyin S, Okoye C, Odion-Omonhimin LO, et al. Safety and efficacy of dupilumab, omalizumab, and mepolizumab in moderate-to-severe asthma: a systematic review. Cureus. 2025;18(7):e88236. https:\/\/doi.org\/10.7759\/cureus.88236.","journal-title":"Cureus"},{"issue":"5","key":"1269_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2025.104705","volume":"46","author":"X Fang","year":"2025","unstructured":"Fang X, Zhou T, Ye F. Analysis of adverse reaction characteristics of four biologics for the treatment of chronic sinusitis with nasal polyps: a descriptive analysis from WHO-Vigi Access. Am J Otolaryngol. 2025;46(5):104705. https:\/\/doi.org\/10.1016\/j.amjoto.2025.104705.","journal-title":"Am J Otolaryngol"},{"issue":"4","key":"1269_CR44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/imm.13124","volume":"158","author":"A Mazzoni","year":"2019","unstructured":"Mazzoni A, Maggi L, Liotta F, Cosmi L, Annunziato F. Biological and clinical significance of T helper 17 cell plasticity. Immunology. 2019;158(4):287\u201395. https:\/\/doi.org\/10.1111\/imm.13124.","journal-title":"Immunology"},{"issue":"10","key":"1269_CR45","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1016\/j.jid.2022.03.013","volume":"142","author":"C Bridgewood","year":"2022","unstructured":"Bridgewood C, Wittmann M, Macleod T, Watad A, Newton D, Bhan K, et al. T helper 2 IL-4\/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17\u2012type diseases, including seronegative arthritis and enthesitis\/enthesopathy, but not to humoral autoimmune diseases. J Invest Dermatol. 2022;142(10):2660\u20137. https:\/\/doi.org\/10.1016\/j.jid.2022.03.013.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"1269_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/exd.70113","volume":"34","author":"S Blunder","year":"2025","unstructured":"Blunder S, Hermann-Kleiter N, Mahmuti R, Hermann M, Ortner D, Reider D, et al. Blocking of IL-4\/IL-13 signalling with dupilumab results in restoration of serum and cutaneous abnormalities in Netherton syndrome. Exp Dermatol. 2025;34(5):e70113. https:\/\/doi.org\/10.1111\/exd.70113.","journal-title":"Exp Dermatol"},{"issue":"30","key":"1269_CR47","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2147\/CCID.S511559","volume":"18","author":"G Lauletta","year":"2025","unstructured":"Lauletta G, Potestio L, Patruno C, De Lucia M, Napolitano M. Effectiveness and safety of dupilumab and tralokinumab for treating atopic dermatitis and pruritic skin disorders in oncological patients: a narrative review. Clin Cosmet Investig Dermatol. 2025;18(30):311\u20137. https:\/\/doi.org\/10.2147\/CCID.S511559.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1269_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100737","volume":"16","author":"AN Sitek","year":"2023","unstructured":"Sitek AN, Li JT, Pongdee T. Risks and safety of biologics: a practical guide for allergists. World Allergy Organ J. 2023;16:100737. https:\/\/doi.org\/10.1016\/j.waojou.2022.100737.","journal-title":"World Allergy Organ J"},{"issue":"20","key":"1269_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14207387","volume":"19","author":"M Latorre","year":"2025","unstructured":"Latorre M, Costanzo G, Ledda AG, Sambugaro G, Cardini C, Sala I. Osteoporosis in severe asthmatic patients: data from the Severe Asthma Network in Italy (SANI) registry. J Clin Med. 2025;19(20):7387. https:\/\/doi.org\/10.3390\/jcm14207387.","journal-title":"J Clin Med"},{"issue":"8","key":"1269_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-025-00705-8","volume":"26","author":"O Shamriz","year":"2025","unstructured":"Shamriz O, Parnasa E, Rubin L, Talmon A, Ribak Y, Hindi I, et al. Dual biological treatments in immune-mediated disorders: a single center experience. BMC Immunol. 2025;26(8):29. https:\/\/doi.org\/10.1186\/s12865-025-00705-8.","journal-title":"BMC Immunol"}],"updated-by":[{"DOI":"10.1007\/s11882-026-01278-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000}}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01269-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-026-01269-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01269-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:16:30Z","timestamp":1778919390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-026-01269-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1269"],"URL":"https:\/\/doi.org\/10.1007\/s11882-026-01269-2","relation":{},"ISSN":["1534-6315"],"issn-type":[{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The original published version of this article unfortunately contained mistakes. The authors identified an error in Table 1 where several tables are overlapping, making the final rows of all tables difficult or impossible to read. These corrections do not affect the scientific content, interpretation, or conclusions of the article. The authors apologize for any inconvenience caused to the readers.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11882-026-01278-1","URL":"https:\/\/doi.org\/10.1007\/s11882-026-01278-1","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Author AID: has received speaker fees from GlaxoSmithKline, Sanofi and Regeneron Pharmaceuticals Inc., AstraZeneca, Viatris, Loafarma, Menarini, Organon, Uriach, Inmunotek, Leti, Diater and Optinose.Author ZA: she has no conflict of interest.Author MV: received remuneration for scientific advisory in the REAL Project from LETI Pharma and in the FARO Project from Astra-Zeneca, for participating in studies conducted by Orion Pharma and Pharmore Research\u00a0and has also received honoraria as a speaker from LETI Pharma, Astra-Zeneca, GSK and Sanofi.Author IA declares to have received honoraria for consultancy and conferences from AstraZeneca, Viatris, Roche, Sanofi, GSK, MSD, Menarini, Salvat, Galenus Health, Olympus, Medtronic, and Novartis.Author JM: has received speaker fees from GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Mylan-Meda Pharmaceuticals (Viatris), Novartis, Regeneron Pharmaceuticals Inc., Sanofi, UCB Pharma, and Uriach; clinical trial funding from Genentech-Roche, Regeneron Pharmaceuticals Inc., and Sanofi; research grants from Mylan-Meda Pharmaceuticals (Viatris) and Uriach; and advisory board fees from Genentech-Roche, Mylan-Meda Pharmaceuticals (Viatris), Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Uriach.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"We confirm that the figure and table are originals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permissions"}},{"value":"JM\u00a0is a Section Editor for the journal Current Allergy and Asthma Reports. He was not involved in the peer-review or handling of the manuscript. The authors have no other competing interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"27"}}